GokalR.Peritoneal dialysis. In: CamersonS., DavisonA.M., GrinfeldJ.P.., eds. Oxford textbook of clinical nephrology.Oxford: Oxford University Press, 1992: 1477–505.
2.
HolmesC.J.Biocompatibility of peritoneal dialysis solutions.Perit Dial Int1993; 13: 88–94.
3.
DobbieJ.Durability of the peritoneal membrane.Perit Dial Int1995; 15(Suppl): S87–94.
4.
KoppleJ., BernardD., MessanaJ.Treatment of malnourished CAPD patients with amino acid based dialysate.Kidney Int1995; 47: 448–57.
5.
JonesM.R.Intraperitoneal amino acids: A therapy whose time has come?Perit Dial Int1995; 15(Suppl): S67–74.
6.
BazzatoG., FracassoA., GambaroG., BaggioB.Use of glycosaminoglycans to increase efficiency of long term continuous peritoneal dialysis.Lancet1995; 346: 740–1.
7.
YasudaT., OzawaS., ShebaC.D-Lactate metabolism in patients with chronic renal failure undergoing CAPD.Nephron1993; 63: 416–22.
8.
BrunkhorstR., MahioutA.Pyruvate as non-toxic peritoneal dialysate buffer; maintained mesothelial cell integrity and proliferation.J Am Soc Nephrol1994; 5: 410.
9.
LiberekT., TopleyN., JörresA., ColesG.A., GahlG.M., WilliamsJ.D.Peritoneal dialysis fluid inhibition of phagocyte function: Effect of osmolality and glucose concentrations.J Am Soc Nephrol1993; 3: 1508–15.
HjelleJ.T., Miller-HjelleM.A., DobbieJ.W.The biology of the mesothelium during peritoneal dialysis.Perit Dial Int1995; 15(7)(Suppl): S13–28.
12.
MahioutA., ErlerdingG., KrautizigS., BrunkhorstR.Production of advanced glycosylation end products (AGE) in the peritoneum of CAPD patients.J Am Soc Nephrol1994; 5: 464.
13.
FlessnerM.F.Osmotic barrier of the parietal peritoneum.Am JPhysiol1994; 267: F861–70.
14.
LambE., Cat tellW., DawnayA.Glycated albumen in serum and dialysate of patients in CAPD.Clin Sci1993; 84: 619–26.
15.
YamadaK., MiyakasaY., HamaguchiK.Immunohistochemical study of human advanced glycosylation end products (AGE) in chronic renal failure.Clin Nephrol1994; 42: 354–61.
16.
MillarD.J., DawnayA.Glycation of albumin with icodextrin.J Am Soc Nephrol1995; 6: 551.
17.
MistryC.D., MallickN.P., GokalR.Ultrafiltration with an isosmotic solution during long peritoneal dialysis exchanges.Lancet1987; ii: 178–82.
18.
MistryC.D., GokalR., PeersE.M., MIDAS Study Group. A randomized multicenter clinical trial comparing isosmolar icodextrin with hyperosmolar glucose in CAPD.Kidney Int1994; 46: 496–503.
19.
SteinA., PeersE., HattersleyJ.Clinical experience with icodextrin in CAPD patients.Perit Dial Int1994; 14(Suppl 2): S51–4.
20.
PosthumaN., WeeP., DoinkerA., OeR.P., VerbrughH.A., PeersE.Improved ultrafiltration in CCPD patients using icodextrin instead of glucose during the long daytime dwell.J Am Soc Nephrol1995; 6: 513.
21.
FallerB., ShockleyT., GenestierS.A comparative clinical study of peritoneal dialysis solutions containing polyglucose in combination with amino acids.J Am Soc Nephrol1995; 6: 510.
22.
MartisL., SerlesK.D., NolphK.Calcium carbonate as a phosphate binder. Is there is a need to adjust peritoneal dialysate calcium concentration for patients using CaCo3.Perit Dial Int1989; 9: 325–8.
23.
HutchisonA., FreemontA.J., BoultonH.F., GokalR.Low calcium dialysis fluid and oral calcium carbonate in CAPD: A method of controlling hyperphosphataemia whilst minimizing aluminum exposure and hypercalcaemia.Nephrol Dial Transplant1992; 7: 1219–25.
CunninghamJ., BeerJ., ColdwellR.D., NoonK., SawyerN., MakinH.Dialysate calcium reduction in CAPD patients treated with calcium carbonate and alfacalcidol.Nephrol Dial Transplant1992; 7: 63–8.
26.
WeinreichT., RitzE., Passlick-DeetjenJ.Long-term dialysis with low calcium solution in CAPD -Effects of bone mineral metabolism.Perit Dial Int1996; 16: 260–8.
27.
HutchisonA., TurnerK., GokalR.Effect of long term therapy with 1.25 mmol/L calcium PD fluid on incidence of peritonitis in CAPD.Perit Dial Int1992; 12: 321–5.
